Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention

International Journal of Cardiology

Volumn 109, Issue 1, 2006, Pages 16-20

  Gunasekara, Athula P ^a   Walters, Darren L ^a   Aroney, Con N ^a  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

Abciximab; Coronary disease; Glycoprotein inhibitor; Stenting; Tirofiban

Indexed keywords

ABCIXIMAB; TIROFIBAN; TROPONIN;

ACUTE CORONARY SYNDROME; ADULT; AMPOULE; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CONTROLLED STUDY; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DEATH; DIABETES MELLITUS; DRUG MEGADOSE; DRUG PACKAGING; FEMALE; HEART INFARCTION; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVASCULARIZATION; STROKE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; AUSTRALIA; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RETROSPECTIVE STUDIES; SYNDROME; TROPONIN; TYROSINE;

EID: 33645418491     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2005.05.045     Document Type: Article

References (17)

1. E.J. Topol, T.V. Byzova, and E.F. Plow Platelet GP IIb-IIIa blockers Lancet 353 1999 227 231
2. J.J. Cook, B. Bednar, J.J. Lynch, R.J. Gould, M.S. Egbertson, and W. Halczenko Tirofiban (aggrastat) Cardiovasc Drug Rev 17 1999 199 224
3. RESTORE investigators Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty Circulation 96 1997 1445 1453
4. E.J. Topol, D.J. Moliterno, H.C. Herrmann, E.R. Powers, C.L. Grines, and D.J. Cohen Comparison of two glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization N Engl J Med 344 2001 1888 1894
5. S.S. Kabbani, A. Aggarwal, E.F. Terrien, P.M. DiBattiste, B.E. Sobel, and D.J. Schneider Suboptimal early inhibition of platelets by treatment with tirofiban and implication for coronary interventions Am J Cardiol 89 2002 647 650
6. H.C. Herrmann, T.A. Swerkosz, S. Kapoor, D.C. Tardiff, P.M. DiBattiste, and J.W. Hirshfeld Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention Am J Cardiol 89 2002 1293 1297
7. D.J. Schneider, H.C. Herrmann, N. Lakkis, F. Aguirre, Y. Wan, and A. Aggarwal Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban Am J Cardiol 90 2002 1421 1423
8. J.R. Kizer, M.R. Mutterrej, W.H. Matthai, J. Mc Connell, H. Nardone, and A.F. Sonel Role of cardiac troponin T in the long-term risk stratification of patients undergoing coronary intervention Eur Heart J 24 2003 1314 1322
9. C.P. Cannon, W.S. Weintraub, L.A. Dempoulos, R. Vicari, M.J. Frey, and N. Lakkis Comparison of early invasive and conservative strategies in patients with unstable coronary syndrome treated with the glycoprotein IIb/IIIa inhibitor tirofiban N Engl J Med 344 2001 1879 1887
10. C.P. Jurgens, H.D. White, J.A. Belardi, C. Macaya, J. Soler-Soler, and B.J. Meyer A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement Clin Ther 24 2002 1332 1344
11. D.J. Schneider, H.C. Herrmann, N. Lakkis, F. Aguirre, M.W. Lo, and K.C. Yin Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus dose of tirofiban Am J Cardiol 91 2003 334 336
12. J.J. Popma, P. Berger, E.M. Ohman, R.A. Harrington, C. Grines, and J.I. Weitz Antithrombotic therapy during percutaneous intervention. (The seventh ACCP conference on antithrombotic and thrombolytic therapy) Chest 126 2004 576S 599S
13. A.E. Abdelmeguid, E.J. Topol, P.L. Whitlow, S.K. Sapp, and S.G. Ellis Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions Circulation 94 1996 1528 1536
14. T.Q. Kong, C.J. Davidson, S.N. Meyers, J.T. Tauke, M.A. Parker, and R.O. Bonow Prognostic implication of creatine kinase elevation following elective coronary artery interventions JAMA 277 1997 461 466
15. S.J. Brener, B.W. Lytle, J.P. Schneider, S.G. Ellis, and E.J. Topol Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality J Am Coll Cardiol 40 2002 1961 1967
16. G.W. Stone, R. Mehran, G. Dangas, A.J. Lansky, R. Kornowski, and M.B. Leon Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients Circulation 104 2001 642 647
17. G.B. Danzi, C. Capuano, M. Sersana, and R. Baglini Safety of a high bolus dose of tirofiban in patients undergoing coronary stent placement Catheter Cardiovasc Interv 61 2004 179 184